Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy Pollock

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Current Opinion in Biotechnology|December 3, 2002
Dimerizer-regulated gene expressionRoy Pollock, Tim Clackson
Nature Biotechnology|June 29, 2002
Regulation of endogenous gene expression with a small-molecule dimerizerRoy Pollock, Maryann Giel, Katja Linher, et al.
Human Gene Therapy|December 22, 2004
Pharmacological regulation of the insulin receptor signaling pathway mimics insulin action in cells transduced with viral vectorsGabriella Cotugno, Roy Pollock, Pietro Formisano, et al.
Molecular Cancer Therapeutics|April 13, 2011
Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimensVictor M Rivera, Rachel M Squillace, David Miller, et al.
Plos One|November 1, 2011
Identification of direct target engagement biomarkers for kinase-targeted therapeuticsCloud P Paweletz, Jannik N Andersen, Roy Pollock, et al.
Blood|July 17, 2004
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CMLThomas O'Hare, Roy Pollock, Eric P Stoffregen, et al.
Blood|May 5, 2018
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemiaEytan M Stein, Guillermo Garcia-Manero, David A Rizzieri, et al.
The Journal of Biological Chemistry|December 2, 2010
Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitorKumiko Nagashima, Stuart D Shumway, Sriram Sathyanarayanan, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Current Opinion in Biotechnology|December 3, 2002
Dimerizer-regulated gene expressionRoy Pollock, Tim Clackson
Nature Biotechnology|June 29, 2002
Regulation of endogenous gene expression with a small-molecule dimerizerRoy Pollock, Maryann Giel, Katja Linher, et al.
Human Gene Therapy|December 22, 2004
Pharmacological regulation of the insulin receptor signaling pathway mimics insulin action in cells transduced with viral vectorsGabriella Cotugno, Roy Pollock, Pietro Formisano, et al.
Molecular Cancer Therapeutics|April 13, 2011
Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimensVictor M Rivera, Rachel M Squillace, David Miller, et al.
Plos One|November 1, 2011
Identification of direct target engagement biomarkers for kinase-targeted therapeuticsCloud P Paweletz, Jannik N Andersen, Roy Pollock, et al.
Blood|July 17, 2004
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CMLThomas O'Hare, Roy Pollock, Eric P Stoffregen, et al.
Blood|May 5, 2018
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemiaEytan M Stein, Guillermo Garcia-Manero, David A Rizzieri, et al.
The Journal of Biological Chemistry|December 2, 2010
Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitorKumiko Nagashima, Stuart D Shumway, Sriram Sathyanarayanan, et al.
Pageof 1